| Peer-Reviewed

Clinicopathological Analysis of 2 Cases of Intracranial Mesenchymal Chondrosarcoma

Received: 1 November 2022     Accepted: 23 November 2022     Published: 30 November 2022
Views:       Downloads:
Abstract

Objective To analyze the clinical imaging data, pathological manifestations, molecular genetic characteristics and treatment of intracranial mesenchymal chondrosarcoma (MC), and to explore its diagnosis, differential diagnosis basis and clinical treatment plan. Methods The clinicopathological features, imaging data and immunophenotype of 2 cases of intracranial MC were retrospectively analyzed, and related literatures were reviewed. Results Both patients were admitted to hospital because of headache and limited vision. Imaging examination showed intracranial and extracerebral lesions (possible meningioma?). Microscopically, the tumor showed bidirectional differentiation and consisted of small round undifferentiated mesenchymal cells with basically the same size and scattered islands of relatively mature hyaline cartilage. Hemangiopericytoma conformation was seen in some areas. Immunophenotype: small round cells CD99 and vimentin (+), Ki-67 proliferation index 15% to 30%, PCK, Syn and NSE (-), chondrocytes S-100 (+), local expression of cartilage matrix collagen II. Conclusion Primary intracranial MC is extremely rare and easy to be misdiagnosed. It needs to be compared with meningiomas, extraosseous Ewing's sarcoma, solitary fibrous tumor/hemangiopericytoma, soft tissue malignant lymphoma, small cell metastatic carcinoma and other types of chondrosarcoma. Phase identification.

Published in American Journal of Clinical and Experimental Medicine (Volume 10, Issue 6)
DOI 10.11648/j.ajcem.20221006.11
Page(s) 124-128
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Intracranial Tumor, Mesenchymal Chondrosarcoma, Clinicopathological Features

References
[1] Harsh GR 4th, Wilson CB. central nervous system mesenchymal chondrosarcoma. Case report [J]. J Neurosurg, 1984, 61 (2): 375-381.
[2] De Cecio R, Migliaccio I, Falleti J, et al. Congenital intracranial mesenchymal chondrosarcoma: case report and review of the literature in pediatric patients [J]. Pediatr Dev Pathol, 2008, 11 (4): 309-313.
[3] Salvati M, Caroli E, Frati A, et al. Central nervous system mesenchymal chondrosarcoma [J]. Exp Clin Cancer Res, 2005, 24 (2): 317-324.
[4] Vergeer RA, Vink R, Avenarius JK, et al. A 71-year-old woman with an intracranial dural-based mesenchymal chondrosar- coma [J]. J Clin Neurosci, 2012, 19 (8): 1170-1.
[5] Cho BK, Chi JG, Wang KC, et al. Intracranial mesenchym alchondrosarcoma: a case report and literature review [J]. Childs Nerv Syst, 1993, 9 (5): 295-9.
[6] Wehrli BM, Huang W, De Crombrugghe B, Ayala AG, Czerniak B: SOX9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol 34: 263-269, 2003.
[7] Madiha S, Sajid M, Asif L et al. NKX3.1 a useful marker formesenchymal chondrosarcoma: An immunohistochemical study [J]. Annals of Diagnostic Pathology 50 (2021) 151660.
[8] Gatter KM, Olson S, Lawce H, et al. Trisomy 8 as the sole cytogenetic abnormality in a case of extraskeletal mesenchymal chondrosarcoma [J]. Cancer Genet Cytogenet, 2005, 159 (2): 151-4.
[9] Crosswell H, Buchino JJ, Sweetman R, et al. Intracranialmesenchymal chondrosarcoma in an infant [J]. Med Pediatr Oncol, 2000, 34 (5): 370-4.
[10] Nyquist KB, Panagopoulos I, Thorsen J, et al. Whole transcriptome sequencing identifis novel IRF2BP2-CDX1 fusion gene brought about by translocation t (1; 5) (q42; q32) in mesenchymal chondrosarcoma [J]. PLoS One, 2012, 7 (11): e49705.
[11] Richkind KE, Romansky SG, Finklestein JZ. t (4; 19) (q35; q13.1): a recurrent change in primitive mesenchymal tumors? [J]. Cancer Genet Cytogenet, 1996, 87 (1): 71-4.
[12] Panagopoulos I, Gorunova L, Bjerkehagen B. Chromosome aberrations and HEY1-NCOA2 fusion gene in a mesenchymal chondro- sarcoma [J]. Oncol Rep, 2014, 32 (1): 40-4.
[13] Wang L, Motoi T, Khanin R, et al. Identification of novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data [J]. Genes Chromosomes Cancer, 2012, 51 (2): 127-39.
[14] EI Beaino M, Roszik J, Livingston JA, et al.: mesenchymal chondrosarcoma: a review with emphasis on its fusion-driven biology.Curr Oncol Rep 20: 37, 2018.
[15] Atsuhito U, Kazuhito K, Atsushi F et al.Intracranial Mesenchymal Chondrosarcoma Lacking the Typical Histopathological Features Diagnosed by HEY1-NCOA2 Gene Fusion [J]. NMC Case Report Journal 2020; 7: 47-52.
[16] Bloch OG, Jian BJ, Yang I et al.A systematic review of Intracranial Mesenchymal Chondrosarcoma and survival.J Clin Neurosci.2015; 16 (12): 1547-51.
[17] Herrera A, Ortega C, Reyes G, et al. Primary orbital mesenchy- mal chondrosarcoma: case report and review of the literature [J]. Case Rep Med, 2012, 2012: 292147.
[18] Huvos AG, Rosen G, Dabska M, et al. Mesenchymal chondrosarcoma: a clinicopathologic analysis of 35 patients with emphasis on treatment [J]. Cancer, 1983, 51 (7): 1230-7.
[19] Frander P, R? hn T, Kihlstr? mL, et al. Combination of microsurgery and Gamma knife surgery for the treatment of intracranial chondrosarcomas [J]. Neurosurg, 2006, 105 (Suppl): 18-25.
[20] Xiao A, Li Z, He X, et al. A rare tentorial mesenchymal chondrosarcoma in posterior cranial fossa: case report [J]. Neurol Neuro-chir Pol, 2014, 48 (4): 287-91.
[21] Cojocaru E, Wilding C, Engelman B, et al. Is the IDH mutation a good target for Chondrosarcoma treatment?Curr Mol Bio Rep.2020; 6 (1): 1-9.
Cite This Article
  • APA Style

    Liang Juan, Qian Lu, Xue Fenglin, Li Ting, Zhou Hongping, et al. (2022). Clinicopathological Analysis of 2 Cases of Intracranial Mesenchymal Chondrosarcoma. American Journal of Clinical and Experimental Medicine, 10(6), 124-128. https://doi.org/10.11648/j.ajcem.20221006.11

    Copy | Download

    ACS Style

    Liang Juan; Qian Lu; Xue Fenglin; Li Ting; Zhou Hongping, et al. Clinicopathological Analysis of 2 Cases of Intracranial Mesenchymal Chondrosarcoma. Am. J. Clin. Exp. Med. 2022, 10(6), 124-128. doi: 10.11648/j.ajcem.20221006.11

    Copy | Download

    AMA Style

    Liang Juan, Qian Lu, Xue Fenglin, Li Ting, Zhou Hongping, et al. Clinicopathological Analysis of 2 Cases of Intracranial Mesenchymal Chondrosarcoma. Am J Clin Exp Med. 2022;10(6):124-128. doi: 10.11648/j.ajcem.20221006.11

    Copy | Download

  • @article{10.11648/j.ajcem.20221006.11,
      author = {Liang Juan and Qian Lu and Xue Fenglin and Li Ting and Zhou Hongping and Bian Li},
      title = {Clinicopathological Analysis of 2 Cases of Intracranial Mesenchymal Chondrosarcoma},
      journal = {American Journal of Clinical and Experimental Medicine},
      volume = {10},
      number = {6},
      pages = {124-128},
      doi = {10.11648/j.ajcem.20221006.11},
      url = {https://doi.org/10.11648/j.ajcem.20221006.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20221006.11},
      abstract = {Objective To analyze the clinical imaging data, pathological manifestations, molecular genetic characteristics and treatment of intracranial mesenchymal chondrosarcoma (MC), and to explore its diagnosis, differential diagnosis basis and clinical treatment plan. Methods The clinicopathological features, imaging data and immunophenotype of 2 cases of intracranial MC were retrospectively analyzed, and related literatures were reviewed. Results Both patients were admitted to hospital because of headache and limited vision. Imaging examination showed intracranial and extracerebral lesions (possible meningioma?). Microscopically, the tumor showed bidirectional differentiation and consisted of small round undifferentiated mesenchymal cells with basically the same size and scattered islands of relatively mature hyaline cartilage. Hemangiopericytoma conformation was seen in some areas. Immunophenotype: small round cells CD99 and vimentin (+), Ki-67 proliferation index 15% to 30%, PCK, Syn and NSE (-), chondrocytes S-100 (+), local expression of cartilage matrix collagen II. Conclusion Primary intracranial MC is extremely rare and easy to be misdiagnosed. It needs to be compared with meningiomas, extraosseous Ewing's sarcoma, solitary fibrous tumor/hemangiopericytoma, soft tissue malignant lymphoma, small cell metastatic carcinoma and other types of chondrosarcoma. Phase identification.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Clinicopathological Analysis of 2 Cases of Intracranial Mesenchymal Chondrosarcoma
    AU  - Liang Juan
    AU  - Qian Lu
    AU  - Xue Fenglin
    AU  - Li Ting
    AU  - Zhou Hongping
    AU  - Bian Li
    Y1  - 2022/11/30
    PY  - 2022
    N1  - https://doi.org/10.11648/j.ajcem.20221006.11
    DO  - 10.11648/j.ajcem.20221006.11
    T2  - American Journal of Clinical and Experimental Medicine
    JF  - American Journal of Clinical and Experimental Medicine
    JO  - American Journal of Clinical and Experimental Medicine
    SP  - 124
    EP  - 128
    PB  - Science Publishing Group
    SN  - 2330-8133
    UR  - https://doi.org/10.11648/j.ajcem.20221006.11
    AB  - Objective To analyze the clinical imaging data, pathological manifestations, molecular genetic characteristics and treatment of intracranial mesenchymal chondrosarcoma (MC), and to explore its diagnosis, differential diagnosis basis and clinical treatment plan. Methods The clinicopathological features, imaging data and immunophenotype of 2 cases of intracranial MC were retrospectively analyzed, and related literatures were reviewed. Results Both patients were admitted to hospital because of headache and limited vision. Imaging examination showed intracranial and extracerebral lesions (possible meningioma?). Microscopically, the tumor showed bidirectional differentiation and consisted of small round undifferentiated mesenchymal cells with basically the same size and scattered islands of relatively mature hyaline cartilage. Hemangiopericytoma conformation was seen in some areas. Immunophenotype: small round cells CD99 and vimentin (+), Ki-67 proliferation index 15% to 30%, PCK, Syn and NSE (-), chondrocytes S-100 (+), local expression of cartilage matrix collagen II. Conclusion Primary intracranial MC is extremely rare and easy to be misdiagnosed. It needs to be compared with meningiomas, extraosseous Ewing's sarcoma, solitary fibrous tumor/hemangiopericytoma, soft tissue malignant lymphoma, small cell metastatic carcinoma and other types of chondrosarcoma. Phase identification.
    VL  - 10
    IS  - 6
    ER  - 

    Copy | Download

Author Information
  • Department of Pathology, Diannan Central Hospital of Yunnan Prov

  • Department of Pathology, The First Affiliated Hospital of Kunmin

  • Department of Pathology, The First Affiliated Hospital of Kunmin

  • Department of Pathology, The First Affiliated Hospital of Kunmin

  • Department of Pathology, The First Affiliated Hospital of Kunmin

  • Department of Pathology, The First Affiliated Hospital of Kunmin

  • Sections